Briacell Therapeutics Corp (BCTX) Stock Analysis
Verdict: AVOID
Negative cash runway of ~5 months and a 92% price collapse signal imminent dilution or insolvency despite speculative clinical upside.
Investment score: 28/100
Analysis as of
Is Briacell Therapeutics Corp stock worth reviewing? The TradeMates thesis
Avoid based on terminal cash burn and lack of fundamental catalysts.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Briacell Therapeutics Corp opportunities and risks
What speaks for BCTX
- Bria-IMT Phase 2 Data Catalyst
What speaks against BCTX
- Imminent Liquidity Rupture
Peers and competitors
- EDSA
- COV.V
- SVA.TO
- ATLE.V
- MBX.TO
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BCTX | n/a | 0.0x | 0.0x | 0.0% | 0.0% | -513.8% |
| EDSA | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.5% |
| COV.V | 34.8x | 1.8x | 20.4x | 53.0% | 5.0% | 8.2% |
| SVA.TO | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.2% |
| MBX.TO | n/a | 2.8x | n/a | 42.5% | -38.6% | -13.3% |
| Peer median | n/a | 0.9x | n/a | 21.2% | 0.0% | -11.3% |
Frequently asked questions about Briacell Therapeutics Corp (BCTX)
Is BCTX stock a good investment?
The TradeMates model rates Briacell Therapeutics Corp as AVOID with an investment score of 28/100. Avoid based on terminal cash burn and lack of fundamental catalysts. This is algorithmic model output, not personal investment advice.
Is BCTX stock a buy?
The TradeMates model verdict for BCTX is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.